<DOC>
	<DOCNO>NCT02351856</DOCNO>
	<brief_summary>This rollover study design investigate safety effectiveness investigational study drug ARRY-371797 patient previously receive ARRY-371797 study patient LMNA-related dilated cardiomyopathy sponsor Array BioPharma may , Investigator 's opinion , derive benefit continue treatment .</brief_summary>
	<brief_title>A Rollover Study ARRY-371797 Patients With LMNA-Related Dilated Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Key Received ARRY371797 treatment genetic dilate cardiomyopathy secondary LMNA mutation clinical study sponsor Array BioPharma . May , opinion Investigator , benefit continue ARRY371797 treatment . Additional criterion exist . Key Discontinued treatment parent study reason study completion Sponsor termination study . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>laminopathy</keyword>
</DOC>